Aeglea Biotherapeutics
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD. For more information, please visit http://aeglea.com.
7-day free trial · no credit card
Verified contacts
13
available on Kipplo
LinkedIn employees
11
51 to 200 range
Open roles
—
no listings
Distinct roles
12
indexed titles
Tech stack
4
tools in use
Monthly traffic
1.6K
organic / mo
Sign up free to see all 13 verified contacts at Aeglea Biotherapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
13 contacts with verified email or phone · masked until revealed.
- CW
Chessa Williams
Senior Clinical Project Manager · Research & Development
EmailPhone - GL
Gail Lawrence
Contract Cra · Other
EmailPhone - MB
Michelle Burgess
Director Quality Operations · Other
EmailPhone - RJ
Ramsey Jenschke
PhD Candidate at Texas A&M | Genetics · Other
EmailPhone
Showing 4 of 13 verified contacts
Top roles at Aeglea Biotherapeutics
12 distinct titles indexed · top 10 shown.
- 1account manager
- 1assoicate director
- 1chief development officer
- 1clinical project manager
- 1contract cra
- 1director quality operations
- 1director, statistical programming
- 1executive assistant
- 1phd candidate at texas a&m | genetics
- 1senior clinical project manager
- +2more titles
Sign up to unlock all 13 contacts at Aeglea Biotherapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 13 verified contacts at Aeglea Biotherapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.